Skip to content

Autoimmune Phenomena After Acute Stroke

Autoimmune Phenomena After Acute Stroke - the Role of Stroke-induced Immunodepression

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01082783
Acronym
ARIMIS
Enrollment
28
Registered
2010-03-09
Start date
2009-12-31
Completion date
2011-11-30
Last updated
2018-11-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Stroke

Keywords

stroke-induced immunodepression, acute media infarct, acute intracerebral bleeding, leucocytes, autoaggressive T-cells, acute media infarct or acute intracerebral bleeding

Brief summary

The damage of the brain parenchyma, as well as the stroke-induced dysfunction of the blood-brain-barrier can make previously hidden CNS antigens visible, and can thus lead to the development of autoimmune mechanisms. It seems plausible that stroke-associated immunodepression influences the development and the phenotype of these autoreactive immune responses. This study will investigate whether cerebral ischemia leads to changes in the immune response, in particular to the development and/or proliferation of autoreactive effector T-cells and/or regulatory T-cells. Furthermore, the association between the severity and the phenotype of this autoimmune response and the clinical course, i.e. prognosis and mortality, will be investigated.

Interventions

None listed

Sponsors

NeuroCure Clinical Research Center, Charite, Berlin
CollaboratorOTHER
Charite University, Berlin, Germany
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* acute media infarct or intracerebral bleeding within the last 36 h (patients) * NIHSS \> 7 (patients) * age \> 17 years (patients), age \> 54 years (controls) * informed consent of patient or legal representative/ of control * cardiovascular risk such as diabetes mellitus (control)

Exclusion criteria

* infections (patients, controls) * antibiotic or immunosuppressive treatment within the last 4 weeks (patients) * other CNS disorders

Design outcomes

Primary

MeasureTime frameDescription
autoantigen-specific T-cells in patients with acute media infarctwithin 36 hquantitative determination of autoantigen-specific T-cells in patients with acute media infarct
leukocytes in patients with acute media infarctwithin 36 hoursquantitative and qualitative analysis of leukocytes in patients with acute media infarct

Secondary

MeasureTime frame
frequency and phenotype of CNS-autoreactive immune cells under the influence of immunodepressionwithin 36 h, after day 3, 7, 90 and 180
clinical course, i.e. mortality and prognosis (measured by mod. Rankin Scale)after day 90 and 180
clinical course, i.e. mortality and prognosis (measured by Bartel Index)after day 90 and 180

Countries

Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026